RxDoctor Payments Data

Joseph Doan, MD

Nephrology · Reno, NVNPI 1528445210

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,690 of the $1,992 with a category attached, or 84.8%. 29 manufacturers reported payments, led by AstraZeneca at 25.9% of the total.

$1,992in general payments, 2019–2025

Across 91 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$516
  • Otsuka America Pharmaceutical, Inc.$231
  • Amgen$206
  • Travere Therapeutics, Inc.$103
  • Bayer$92
  • Vifor Pharma, Inc.$81
  • plus $763 from 23 others

What the payments were for

  • Food & beverage$1,69085%
  • Education$30215%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,992 in reported general payments places this provider in the 55th percentile of 125 nephrology providers in Nevada.

See all nephrology providers in Nevada

Medicare billing

Part B allowed, 2024
$169,762
Medicare patients
359
Services billed
1,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol21$33,841
JardianceEmpagliflozin16$21,630
Sevelamer Carbonate12$3,466
Losartan Potassium72$815
Amlodipine Besylate65$428
Tamsulosin Hcl19$373
Furosemide37$249
Lisinopril35$230
Allopurinol15$174
Hydralazine Hcl26$159
Hydrochlorothiazide25$131
Torsemide11$126
Spironolactone15$87
Carvedilol13$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$516$33,84121 claims
Boehringer IngelheimJardiance$45$21,63016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 125 nephrology providers in Nevada.

Other nephrology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →